RxDoctor Payments Data

Larissa May, MD

Emergency Medicine · Washington, DCNPI 1083624282

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (59.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Gilead at 46.9% of the total. Among emergency medicine clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$174,159in general payments, 2019–2025

Across 114 payments — averaging $1527.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$82K
  • Biomerieux Inc$25K
  • Roche Diagnostics Corporation$11K
  • Roche Molecular Systems, Inc.$9K
  • Abbott$9K
  • Ferring Pharmaceuticals Inc.$9K
  • plus $28K from 12 others
$760,199in research payments, 2019–2025

Across 28 payments — averaging $27,150 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biofire Diagnostics, LLC$278K
  • Roche Molecular Systems, Inc.$203K
  • Merck$199K
  • Roche Diagnostics Corporation$54K
  • Gilead$26K

What the payments were for

  • Consulting fees$103,18659%
  • Speaking & faculty fees$61,73935%
  • Travel & lodging$5,7653%
  • Food & beverage$3,4402%
  • Education$290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead15$81,764
Biomerieux Inc19$25,407
Roche Diagnostics Corporation14$11,352
Roche Molecular Systems, Inc.10$9,283
Abbott5$9,111
Ferring Pharmaceuticals Inc.17$9,021
Biofire Diagnostics, LLC9$8,276
Fisher Scientific Company L.L.C.6$6,508
Genmark Diagnostics, Inc.2$5,478
Cepheid7$5,280
La Jolla Pharmaceutical Company1$1,500
Talis Biomedical Corporation1$375
GSK1$325
Opgen, Inc.1$221
Novavax Inc1$97
Bio-rad Laboratories, Inc.3$83
Janssen Research & Development, LLC1$48
Astellas Pharma US Inc1$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$174,159 in reported general payments places this provider in the 95th percentile of 271 emergency medicine providers in District of Columbia.

See all emergency medicine providers in District of Columbia

Medicare billing

Part B allowed, 2024
$7,974
Medicare patients
66
Services billed
69

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Omeprazole11$43

Paid to pharmacies, not to this prescriber.

Other emergency medicine in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →